Armodafinil

What armodafinil is

Armodafinil is a wakefulness-promoting drug, a so-called eugeroic. In the US it has been approved as Nuvigil since 2007, for excessive sleepiness in sleep apnea, narcolepsy and shift work disorder. In Germany there is no approved product, unlike the mixture modafinil.

What is rated is the state of knowledge. For the US indications it is good, with several double-blind studies and objective wakefulness tests. For use as a smart drug in well-rested healthy people there are no armodafinil-specific studies; here one relies on the data on modafinil.

How it works

Modafinil is a racemate, that is, a 1:1 mixture of R- and S-modafinil. The S-form is broken down rapidly after intake; the R-form stays in the blood longer. In pooled data from three studies in healthy people, the half-life of both products was the same at about 13 hours, but the total amount in the blood was 33 to 40 percent higher under armodafinil for the same milligram amount, and levels remained higher later in the day (Darwish 2009). This is the basis of the expectation that armodafinil keeps people awake longer.

The site of action is considered the same as with modafinil. According to the US prescribing information, the substance binds to the dopamine reuptake transporter and increases dopamine outside the nerve cells without increasing dopamine release. The imaging data in humans come from modafinil; a dedicated imaging study on armodafinil was not found in the research.

What the studies show

Harsh 2006: narcolepsy

Harsh 2006 (Curr Med Res Opin) randomized 196 adults with narcolepsy to two dose levels of armodafinil or placebo for 12 weeks. In the maintenance of wakefulness test (MWT), mean sleep latency lengthened by 1.3 and 2.6 minutes; under placebo it shortened by 1.9 minutes, p<0.01. Memory, attention and fatigue also improved significantly. The most common side effects were headache, nausea and dizziness.

Czeisler 2009: shift work disorder

Czeisler 2009 (Mayo Clin Proc) treated 254 night or rotating shift workers with shift work disorder for 12 weeks before each night shift. Sleep latency in the laboratory test rose to 5.3 versus 2.8 minutes under placebo, p<0.001. The clinical condition improved in 79 versus 59 percent. Mean sleep latency thus remained in the range considered severe sleepiness during the day; sleepiness also decreased on the commute home, and daytime sleep did not change.

Gasior 2014: healthy men without sleep

In this study, armodafinil was the active comparator for lisdexamfetamine. 135 healthy men stayed awake for 24 hours and received a single dose. In the maintenance of wakefulness test they lasted 27.6 minutes under armodafinil, 15.3 minutes under placebo, p<0.0001; the reaction time task went better. Headache occurred in 7.4 versus 3.7 percent.

Tembe 2011: armodafinil versus modafinil

The only direct comparison found: 211 patients with shift work disorder in India received armodafinil or modafinil double-blind for 12 weeks. Response was 72.1 versus 74.3 percent, p=0.76; side effects were comparable. No advantage of armodafinil was found.

Bipolar depression: two studies, two results

As an add-on to mood-stabilizing maintenance treatment, armodafinil lowered depression scores more than placebo in Calabrese 2014 in 433 patients, but the remission rate did not differ (21 versus 17 percent). The follow-up study Ketter 2015 with 462 patients in the two main groups missed its goal, p=0.13. A meta-analysis of five studies with modafinil or armodafinil found more response (RR 1.18) and remission (RR 1.38) overall. This use is not approved anywhere.

Where the data stop

• More effect than modafinil. The higher levels in the afternoon have been measured; a clinical advantage has not: in the only direct comparison, both were equally effective.
• Cognition in well-rested people. No armodafinil-specific studies on memory, concentration or productivity in well-rested healthy people were found. What circulates on this comes from modafinil studies, which show a small effect in well-rested people.
• Continuous use by healthy people. The studies run for a few months at most and include patients with sleep disorders. Data on regular use by healthy people over years are missing.
• Products without approval. In Germany there is no approved product. For tablets from the gray market, neither the studies nor the quality controls of the US approval apply.

Status, approval and legal

In Germany no medicine containing armodafinil is approved, and the European Medicines Agency’s list of medicines contains no central EU authorization. Armodafinil is not listed in the German Narcotics Act (BtMG). The German Prescription Drugs Ordinance (AMVV) lists modafinil in Annex 1; armodafinil is not listed there separately. Finished medicinal products may only be placed on the market in Germany with an authorization (§ 21 AMG).

In the US, armodafinil has been approved as Nuvigil since 15.06.2007, to improve wakefulness in adults with excessive sleepiness due to obstructive sleep apnea, narcolepsy or shift work disorder. There it is classified as Schedule IV, that is, as a controlled substance with abuse potential. Use for performance enhancement in healthy people is not approved anywhere.

In sport, armodafinil is prohibited in competition: the World Anti-Doping Agency’s 2026 Prohibited List lists modafinil under S6.A, the non-specified stimulants, and explicitly covers all optical isomers.

Safety

The most common side effects in the controlled studies were headache, nausea, dizziness and insomnia. According to the US prescribing information, serious skin reactions up to Stevens-Johnson syndrome occur, as well as DRESS, a hypersensitivity reaction involving several organs, and angioedema and anaphylaxis. In the event of a rash, armodafinil should be stopped immediately unless the rash clearly has another cause.

Psychiatric side effects have been described; particular caution applies with a history of psychosis, depression or mania. With known cardiovascular disease, the prescribing information recommends closer monitoring. After market launch, abuse, dose escalation and diversion were reported.

For pregnancy the data are insufficient; under armodafinil and modafinil, growth retardation and miscarriages have been reported. If you use hormonal contraception: for modafinil it is established that it weakens the effect of hormonal contraceptives, which is described on the modafinil page.

Sources

• Harsh JR et al., Curr Med Res Opin 2006 – armodafinil in narcolepsy, RCT with 196 patients
• Czeisler CA et al., Mayo Clin Proc 2009 – armodafinil in shift work disorder, RCT with 254 night workers
• Gasior M et al., J Clin Psychopharmacol 2014 – wakefulness after 24 hours of sleep deprivation, 135 healthy men
• Darwish M et al., Clin Drug Investig 2009 – differing pharmacokinetics of armodafinil and modafinil
• Tembe DV et al., Neurol Res Int 2011 – armodafinil versus modafinil in shift work disorder, RCT with 211 patients
• Calabrese JR et al., J Clin Psychiatry 2014 – armodafinil as add-on in bipolar depression, 433 patients
• Ketter TA et al., J Affect Disord 2015 – second phase 3 trial in bipolar depression, goal missed
• Nunez NA et al., Bipolar Disord 2020 – meta-analysis of modafinil/armodafinil in bipolar depression, 5 RCTs
• FDA, Drugs@FDA – Nuvigil (NDA 021875), approval 15.06.2007, prescribing information
• WADA Prohibited List 2026 (bilingual version by JADA)